Skip to content
Head to head

Ionis Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: IONS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

IONS -63.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
IONSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price26.58515.02
Change today-2.35%-1.08%
1-year return-63.6%+22.0%
Market cap$4.43B$130.58B
52-week range26.53 – 86.74412.27 – 568.67
Valuation
P/E (TTM)-7.9333.14
P/E percentile, own 5-yr range89th99th
P/B11.246.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.3815.32
Net profit (TTM)$-396.38M$3.88B
Revenue (TTM)$960.09M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+54.9%+11.8%
Gross margin98.2%85.5%
Operating margin-58.8%33.1%
Net margin-56.9%30.7%
Free cash flow (TTM)$-622.77M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership114.7%96.8%
Insider activity (12mo)29 buy / 21 sell28 buy / 22 sell
Short interest (% of float)12.7%1.9%
Analyst consensus95% buy / 5% hold (19)95% buy / 5% hold (21)
Analyst price target$72 (+172%)$624 (+21%)
StockVane view
StockVane Quant RatingE (3)C (68)
Company
Employees1,4026,400
Founded19891989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.